ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Ono Pharmaceutical Co., Ltd.

  • 2,015.00 JPY
  • +0.50
  • +0.02%
  • Japan
    Jul 12, 2019
  • Ticker
    TKS(4528)
  • Prev. close
    2,014.5
  • Market cap (JPY)
    1,094.56B
  • Market cap (USD)
    10,133.41M
  • Shares
    543.34M

Business Summary

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue288,634M2,602.77M
Gross Profit202,772M1,828.50M
Operating income64,764M584.01M
Income before tax65,141M587.41M
Net income51,539M464.75M
EBITDA75,385M679.78M
Diluted EPS100.230.90
Dividends Per Share450.40
Total Assets655,056M5,918.20M
Total liabilities92,320M834.07M
Total equity557,350M5,035.46M
Operating cash flow66,774M602.13M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 135,775M 160,284M 244,797M 261,836M 288,634M
Gross Profit 99,241M 117,409M 177,884M 194,743M 202,772M
Operating income 15,355M 30,014M 59,718M 59,569M 64,764M
Income before tax 18,305M 33,272M 74,540M 63,922M 65,141M
Net income 12,976M 24,979M 55,793M 50,284M 51,539M
EBITDA 21,455M 36,548M 67,539M 68,782M 75,385M
Diluted EPS 24.48 47.13 105.26 96.99 100.23
Dividends Per Share 36 36 40 45 45
Total Assets 524,588M 540,450M 617,461M 609,226M 655,056M
Total liabilities 49,375M 64,195M 92,118M 79,012.59M 92,320M
Total equity 470,575M 471,393M 519,110M 524,390M 557,350M
Operating cash flow 31,579M 12,842M 74,450M 15,727M 66,774M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 1,235.93M 1,334.76M 2,260.62M 2,362.44M 2,602.77M
Gross Profit 903.36M 977.72M 1,642.70M 1,757.09M 1,828.50M
Operating income 139.77M 249.94M 551.47M 537.46M 584.01M
Income before tax 166.62M 277.07M 688.35M 576.74M 587.41M
Net income 118.11M 208.01M 515.23M 453.69M 464.75M
EBITDA 195.30M 304.35M 623.70M 620.59M 679.78M
Diluted EPS 0.22 0.39 0.97 0.87 0.90
Dividends Per Share 0.32 0.29 0.36 0.40 0.40
Total Assets 4,374.30M 4,808.48M 5,541.24M 5,728.49M 5,918.20M
Total liabilities 411.71M 571.15M 826.68M 742.94M 834.07M
Total equity 3,923.91M 4,194.07M 4,658.61M 4,930.79M 5,035.46M
Operating cash flow 287.45M 106.94M 687.52M 141.89M 602.13M

Valuation Measures

Mar 2019
PER21.63
ROA8.15%
ROE9.52%
Operating margin22.43%
Profit margin17.85%

Key executives

  • President & Representative Director: Gyo Sagara
  • Director & General Manager-Operations: Kei Sano
  • Director & Executive Vice President: Hiroshi Awata
  • Executive Officer & Manager-NV Strategy Planning: Shozo Matsuoka
  • Executive Officer & GM-Business Strategy: Toichi Takino

Shareholders

  • Wellington Management Co. LLP (6.8%)
  • Ono Pharmaceutical Co., Ltd. (6.3%)
  • Meiji Yasuda Life Insurance Co. (3.4%)
  • Ono Shogakukai Foundation (3.0%)
  • Kakumeiso Co. Ltd. (2.9%)
  • The Vanguard Group, Inc. (2.1%)
  • Nomura Asset Management Co., Ltd. (1.7%)
  • Mitsubishi UFJ Financial Group, Inc. (1.5%)
  • MS&AD Insurance Group Holdings, Inc. (1.5%)
  • T&D Holdings, Inc. (1.4%)

Contact Details

  • Website:http://www.ono.co.jp
  • Address: 1-8-2 Kyutaromachi, Chuo-Ku, Osaka, 541-8564, Japan
  • Phone: +81.6.6263.5670

Related Companies

  • Ono Pharma Korea Co., Ltd.
  • Ono Pharma UK Ltd.
  • Ono Pharma USA, Inc.
  • Ono Shogakukai Foundation

Competitors

  • Agenus Inc.
  • Calithera Biosciences, Inc.
  • Cytokinetics, Incorporated
  • VistaGen Therapeutics, Inc.
  • BioLineRX Ltd.
  • Crinetics Pharmaceuticals Inc
  • Qurient Co., Ltd.
Last Updated on 12 Jul, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media